KyungdongPharm
Financials
Valuation Metrics
KyungdongPharm's Market Cap is ₩1551B. At end of 2025 it was ₩1797B. Ranked #1005 of 2,421 in KR market (top 42%), #507 of 1,640 on KOSDAQ (top 31%), #113 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 49%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 155.07B KRW | KR#1,005/2,421 Sec#113/231 |
| Revenue | 201.12B KRW | KR#1,035/2,421 Sec#61/231 |
| Net Income | 17.73B KRW | KR#750/2,421 Sec#49/231 |
| Total Assets | 307.84B KRW | KR#1,019/2,421 Sec#67/231 |
| Net Assets | 231.58B KRW | KR#863/2,421 Sec#59/231 |
| Employees | 383 | KR#638/2,421 Sec#55/231 |
| Value | ||
| P/E | 8.75x | KR#720/2,421 Sec#33/231 |
| P/B | 0.67x | KR#1,078/2,421 Sec#57/231 |
| PEG | 0.01x | KR#73/2,421 Sec#4/231 |
| P/S | 0.77x | KR#1,215/2,421 Sec#64/231 |
| EV/EBITDA | 14.21x | KR#823/2,421 Sec#48/231 |
| FCF Yield | -0.94% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 7.66% | KR#824/2,421 Sec#58/231 |
| ROA | 5.76% | KR#650/2,421 Sec#53/231 |
| Op. Margin | 5.85% | KR#857/2,421 Sec#64/231 |
| Revenue Growth | 3.46% | KR#1,294/2,421 Sec#131/231 |
| Earnings Growth | 1550.53% | KR#46/2,421 Sec#4/231 |
| Financial Health | ||
| Debt Ratio | 32.93% | KR#648/2,421 Sec#75/231 |
| Total Debt | 25.40B KRW | KR#1,296/2,421 Sec#101/231 |
| FCF | -1.46B KRW | KR#1,305/2,421 Sec#101/231 |
| Cash | 13.14B KRW | KR#1,524/2,421 Sec#123/231 |
| Current Ratio | 1.77x | KR#993/2,421 Sec#110/231 |
| Net Debt/EBITDA | 1.04x | KR#739/2,421 Sec#49/231 |
| Dividend | ||
| Div. Yield | 5.96% | KR#193/2,421 Sec#4/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -15.15% | KR#1,120/2,421 Sec#73/231 |
| 1M Return | 0.40% | KR#1,184/2,421 Sec#90/231 |
| From 52W High | -19.62% | KR#248/2,421 Sec#10/231 |
| 1Y MDD | -23.38% | KR#112/2,421 Sec#8/231 |
| Trading | ||
| Volume | 13,399 shares | KR#1,787/2,421 Sec#177/231 |
| Trading Value | 67.5M KRW | KR#1,725/2,421 Sec#176/231 |
| Foreign Own. | 1.98% | KR#1,636/2,421 Sec#159/231 |
| Per Share | ||
| EPS | 576 KRW | KR#941/2,421 Sec#66/231 |
| BPS | 7,527 KRW | KR#1,172/2,421 Sec#86/231 |
Company Info
Kyungdong Pharm, established in 1976, manufactures and sells pharmaceuticals, specializing in professional medications like circulatory and digestive system agents, and antihypertensive drugs, including products such as Duoroban Tablets and Alfortin Soft Capsules. The company boasts state-of-the-art solid formulation and injectable manufacturing facilities that meet EU-GMP and US c-GMP standards. Leveraging proprietary raw material synthesis and formulation technologies, it achieves continuous revenue growth through combination drug development, increased investment in biotech firms, and the launch of its WIAVIM health functional food brand.